MRTX1133 attenuates KRASG12D mutated-colorectal cancer progression through activating ferroptosis activity via METTL14/LINC02159/FOXC2 axis
Colorectal cancer (CRC) ranks as the third most commonly diagnosed cancer and the second leading cause of cancer-related deaths worldwide. Studies have shown that CRC patients with KRAS mutations, especially KRASG12D, have an increased risk of metastasis. Emerging evidence indicates that long non-co...
Saved in:
| Main Authors: | Junwei Zou, Xiuhua Shi, Zhaoying Wu, Siyuan Zuo, Xiaolei Tang, Hailang Zhou, Yong Huang |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-02-01
|
| Series: | Translational Oncology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1936523324003619 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Investigation of potential KRASG12D inhibitors: a comparative study between MRTX1133 and natural compounds via computational structural biology approaches
by: Safiye Merve Bostancioglu, et al.
Published: (2025-07-01) -
Study on the mechanism of KRAS R68G secondary mutation-induced resistance to KRASG12D-targeted inhibitor MRTX1133
by: WANG Gaoming, et al.
Published: (2025-06-01) -
Pharmacokinetics, bioavailability, and tissue distribution of MRTX1133 in rats using UHPLC-MS/MS
by: Wei Lu, et al.
Published: (2024-12-01) -
Reactivation of MAPK-SOX2 pathway confers ferroptosis sensitivity in KRASG12C inhibitor resistant tumors
by: Kai Wang, et al.
Published: (2024-12-01) -
Targeting DNA helicase CMG complex and NFκB2-driven drug-resistant transcriptional axis to effectively treat KRASG12D-mutated pancreatic cancer
by: Jeffrey Xiao, et al.
Published: (2025-05-01)